Effect of Zoledronic Acid on Muscle Metabolism in Mice with Osteoporosis Combined with Sarcopenia

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Specialties Orthopedics
Physiology

Date 2024 Nov 22

PMID 39574042

Authors

Weilong Li

Ming Xu

Xuchao Shi

Jie Gu

Jian Guo

Yuanlin Xu

Bo Dai

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the effects of zoledronic acid on muscle metabolism in mice with osteoporosis and sarcopenia and elucidate the possible underlying mechanism.

Methods: Twenty-four 8-week-old male C57BL/6J mice were randomly divided into four groups: non-suspension (N-SUS), suspension (SUS), suspension + zoledronic acid (ZA), and suspension + PTH(PTH) groups. Equal doses of saline, zoledronic acid, and PTH were administered subcutaneously. After 4 weeks, the mice were sacrificed, and body weight and muscle mass (gastrocnemius and soleus) were measured, the right tibia of mice was taken for micro-CT examination, and the muscle specimens were analyzed using HE staining, ATPase staining, western blotting, and real-time PCR.

Results: Compared with the N-SUS group, the bone mineral density (BMD), trabecular bone relative volume (BV/TV) and trabecular bone number (Tb.N) were significantly decreased in the SUS group (P < 0.01), the trabecular bone separation(Tb.Sp)was significantly increased (P < 0.01), which was reversed in ZA and PTH group (P < 0.01).Compared to the SUS group, the body and muscle weights of the ZA and PTH groups were significantly increased. Compared to the SUS group, the muscle structure was less damaged, the proportion of type I muscle fibers was increased, and the protein expression of β-catenin and AKT were upregulated in the ZA and PTH groups(P < 0.05). In addition, the mRNA expression levels of Wnt3a, Wnt16, Myf5, and PI3K were significantly increased (P < 0.05), where as those of Myogenic Differentiation Antigen(MyoD )and Myogenin (MyoG) were significantly decreased (P < 0.05). No significant differences were observed between the ZA and PTH groups.

Conclusions: Zoledronic acid can reduce muscle loss and damage by upregulating the mRNA expression of Wnt and PI3K and the protein expression of β-catenin and AKT.Our results provide a novel basis for the development of drugs for the treatment of osteoporosis combined with sarcopenia.

References

Hughes S, Koishi K, Rudnicki M, Maggs A . MyoD protein is differentially accumulated in fast and slow skeletal muscle fibres and required for normal fibre type balance in rodents. Mech Dev. 1997; 61(1-2):151-63. DOI: 10.1016/s0925-4773(96)00631-4. View

Romanick M, Thompson L, Brown-Borg H . Murine models of atrophy, cachexia, and sarcopenia in skeletal muscle. Biochim Biophys Acta. 2013; 1832(9):1410-20. PMC: 3687011. DOI: 10.1016/j.bbadis.2013.03.011. View

Tsika R, Herrick R, Baldwin K . Effect of anabolic steroids on skeletal muscle mass during hindlimb suspension. J Appl Physiol (1985). 1987; 63(5):2122-7. DOI: 10.1152/jappl.1987.63.5.2122. View

He Z, Nie P, Lu J, Ling Y, Guo J, Zhang B . Less mechanical loading attenuates osteoarthritis by reducing cartilage degeneration, subchondral bone remodelling, secondary inflammation, and activation of NLRP3 inflammasome. Bone Joint Res. 2021; 9(10):731-741. PMC: 7640939. DOI: 10.1302/2046-3758.910.BJR-2019-0368.R2. View

Wronski T, Morey-Holton E . Skeletal response to simulated weightlessness: a comparison of suspension techniques. Aviat Space Environ Med. 1987; 58(1):63-8. View

Li W, Wang X, Chu Y, Wang J, Xu S . Association of sarcopenia and vitamin D deficiency with glucocorticoid-induced osteoporosis in Chinese patients with rheumatoid arthritis. Clin Rheumatol. 2023; 43(1):15-22. DOI: 10.1007/s10067-023-06784-5. View

Hain B, Jude B, Xu H, Smuin D, Fox E, Elfar J . Zoledronic Acid Improves Muscle Function in Healthy Mice Treated with Chemotherapy. J Bone Miner Res. 2019; 35(2):368-381. DOI: 10.1002/jbmr.3890. View

Miedany Y, El Gaafary M, Toth M, Hegazi M, Aroussy N, Hassan W . Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia?. Clin Rheumatol. 2021; 40(10):4225-4232. DOI: 10.1007/s10067-021-05757-w. View

Essex A, Pin F, Huot J, Bonewald L, Plotkin L, Bonetto A . Bisphosphonate Treatment Ameliorates Chemotherapy-Induced Bone and Muscle Abnormalities in Young Mice. Front Endocrinol (Lausanne). 2019; 10:809. PMC: 6877551. DOI: 10.3389/fendo.2019.00809. View

10.

Haeri N, Perera S, Greenspan S . Does Zoledronic Acid Improve Appendicular Lean Mass in Older Women with Osteoporosis? A Sub-Analysis of a Randomized Clinical Trial. J Frailty Aging. 2022; 11(4):420-425. PMC: 9851771. DOI: 10.14283/jfa.2022.54. View

11.

Wannenes F, Papa V, Greco E, Fornari R, Marocco C, Baldari C . Abdominal Fat and Sarcopenia in Women Significantly Alter Osteoblasts Homeostasis In Vitro by a WNT/ β -Catenin Dependent Mechanism. Int J Endocrinol. 2014; 2014:278316. PMC: 4054618. DOI: 10.1155/2014/278316. View

12.

Heng M, Chan A, Man R, Fenwick E, Chew S, Tay L . Individual and combined associations of sarcopenia, osteoporosis and obesity with frailty in a multi-ethnic asian older adult population. BMC Geriatr. 2023; 23(1):802. PMC: 10696759. DOI: 10.1186/s12877-023-04500-1. View

13.

Potsch M, Tschirner A, Palus S, von Haehling S, Doehner W, Beadle J . The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. J Cachexia Sarcopenia Muscle. 2013; 5(2):149-58. PMC: 4053568. DOI: 10.1007/s13539-013-0125-7. View

14.

Rosenberg I . Sarcopenia: origins and clinical relevance. J Nutr. 1997; 127(5 Suppl):990S-991S. DOI: 10.1093/jn/127.5.990S. View

15.

VAN Doorslaer DE Ten Ryen S, Warnier G, Gnimassou O, Belhaj M, Benoit N, Naslain D . Higher strength gain after hypoxic vs normoxic resistance training despite no changes in muscle thickness and fractional protein synthetic rate. FASEB J. 2021; 35(8):e21773. DOI: 10.1096/fj.202100654RR. View

16.

Hassouneh L, Timofiychuk O, Babenko N . Acid sphingomyelinase inhibitors, imipramine and zoledronic acid, increase skeletal muscle tissue sensitivity to insulin action at old age. Gen Physiol Biophys. 2017; 37(2):163-174. DOI: 10.4149/gpb_2017020. View

17.

Miyazaki S, Tamaki A, Wakabayashi H, Arai H . Definition, diagnosis, and treatment of respiratory sarcopenia. Curr Opin Clin Nutr Metab Care. 2023; 27(3):210-218. DOI: 10.1097/MCO.0000000000001003. View

18.

Yang S, Hoy M, Fuller B, Sales K, Seifalian A, Winslet M . Pretreatment with insulin-like growth factor I protects skeletal muscle cells against oxidative damage via PI3K/Akt and ERK1/2 MAPK pathways. Lab Invest. 2010; 90(3):391-401. DOI: 10.1038/labinvest.2009.139. View

19.

Han J, Choi S, Choi R, Park K, Kang K, Lee M . Anti-muscle atrophy effect of fermented Tenebrio molitor larvae extract by modulating the PI3K-Akt-mTOR/FoxO3α pathway in mice treated with dexamethasone. Biomed Pharmacother. 2024; 178:117266. DOI: 10.1016/j.biopha.2024.117266. View

20.

Fellner C, Schick F, Kob R, Hechtl C, Vorbuchner M, Buttner R . Diet-induced and age-related changes in the quadriceps muscle: MRI and MRS in a rat model of sarcopenia. Gerontology. 2014; 60(6):530-8. DOI: 10.1159/000360289. View